Duchenne Muscular Dystrophy (DMD) Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2016 and Forecast 2017-2024

Global Duchenne Muscular Dystrophy (DMD) Treatment Market: Duchenne muscular dystrophy (DMD) is a genetic disorder and it is one of the 9 types of muscular dystrophy, which is characterized by progressive degeneration and weakness of muscle. It is caused due to the absence of dystrophin protein which helps to keep muscle cells intact. Onset of symptoms will be from early childhood in the age of 3-5. Guillaume Benjamin Amand Duchenne was the first French neurologist to describe about Duchenne muscular dystrophy in 1860’s.There is no known cure for duchenne muscular dystrophy but the treatment is given to control the symptoms to maximize the quality of life of the patient.


Increase in the prevalence rate of duchenne muscular dystrophy is the major factor expected to drive the market growth of duchenne muscular dystrophy treatment. As per, NHS estimation 100 are born with duchenne muscular dystrophy every year in UK, while 349 new cases were reported in US in 2010 as per to Centre for Disease Control. Furthermore, Increasing in healthcare expenditure and growing awareness about duchenne muscular dystrophy is also propelling the growth of the duchenne muscular dystrophy treatment market. However, low treatment seeking rate because of delayed diagnosis and fast prognosis of the disorder are the factors which are restraining the growth of duchenne muscular dystrophy.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-duchenne-muscular-dystrophy-treatment-market/#ulp-4H8Z4LpNMLEuOnnx



The Duchenne Muscular Dystrophy (DMD) Treatment Market is classified on the basis of drug class, infection type distribution channel, and geography.


Based on drug class, the Duchenne muscular dystrophy (DMD) Treatment Market is segmented into the following

• Corticosteroids
• Pain management drugs


Based on distribution channel, the Duchenne Muscular Dystrophy (DMD) Treatment Market is segmented into the following

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-duchenne-muscular-dystrophy-treatment-market/#ulp-c654SbFYO64MsOhu

There are very few products are marketed for treatment of duchenne muscular dystrophy like Translama, Exondys 51 and Emflaza. Presently this market is in research phase majorly and focuses on the on-going clinical trials for the development of innovative products. Government organizations are focussing on the prevention of duchenne muscular dystrophy. For instance, world duchenne awareness day was initiated by The United Parent Projects Muscular Dystrophy (UPPMD) with the motto of raising awareness regarding duchenne muscular dystrophy globally and they have declared 07 th September as the world’s duchenne awareness day. In 2015, U.S. FDA has published a specific guidance for development of drugs to treat duchenne muscular dystrophy.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-duchenne-muscular-dystrophy-treatment-market/#ulp-14mlyhjMGhVjZqa3

On the basis of geographical regions, Duchenne Muscular Dystrophy (DMD) treatment market is classified as into five key regions as Europe, Asia- Pacific, North America, Middle East & Africa and Latin America. European region is the dominating market in global DMD treatment market owing to the several treatments for DMD which are approved and are under review in EU. For instance, PTC Therapeutics has recently received orphan drug designation and conditional approval for its Translarna, a gene therapy to treat DPD.


Some of the players in Duchenne muscular dystrophy (DMD) Treatment Market are Bristol-Myers Squibb(U.S), FibroGen, Inc (U.S), ITALFARMACO S.p.A. (Italy), Catabasis Pharmaceuticals, Inc.(U.S) , NS Pharma, Inc. (U.S), Marathon Pharmaceuticals, LLC (U.S), ReveraGen BioPharma, Inc. (U.S), Pfizer (U.S), Summit Therapeutics plc (U.K), Taiho Pharmaceutical Co (Japan), Sarepta Therapeutics (U.S), Inc.,Santhera Pharmaceuticals,PTC Therapeutics (Switzerland).


Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-duchenne-muscular-dystrophy-treatment-market/

About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

This release was published on openPR.